1. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies;Acosta A.;Cochrane Database Syst. Rev.,2014
2. Belloni A. Morgan D. Paris V.(2016).Pharmaceutical expenditure and policies. OECD health working papers no. 87 OECD publishing Paris.
3. Datamonitor Healthcare(2019).Market access trends in the US Europe and emerging markets.https://pharmaintelligence.informa.com/∼/media/informa‐shop‐window/pharma/2019/files/whitepapers/global‐market‐access‐whitepaper_.pdf. Retrieved August 30 2019.
4. Deloitte Report(2019).Global Health Care Outlook.https://www2.deloitte.com/lu/en/pages/life‐sciences‐and‐healthcare/articles/global‐health‐care‐sector‐outlook.html#:∼:text=Global%20health%20care%20expenditures%20are trillion%20to%20USD%20%2410.059%20trillion.&text=The%20health%20care%20market%20is mergers%2C%20acquisitions%2C%20and%20partnerships.
5. Fassbender M.(2016).Tufts examines $2.87bn product lifecycle cost per approved drug.https://www.outsourcing‐pharma.com/Article/2016/03/14/Tufts‐examines‐2.87bn‐drug‐development‐cost. Retrieved August 30 2019.